Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED
Janssen-Cilag International N.V.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection
Janssen-Cilag International N.V.
Acute Myeloid Luekemia
1 trial -
JNJ-77242113
Janssen Cilag International NV
Plaque Psoriasis
1 trial -
JNJ-77242113, Film-Coated Tablet without JNJ-77242113
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
JNJ-77242113-AAC Placebo tablet, JNJ-77242113
Janssen-Cilag International N.V.
Active Psoriatic Arthritis
1 trial -
JNJ-80202135, Placebo subcutaneous without Nipocalimab
Janssen-Cilag International N.V.
Systemic Lupus Erythematosus
1 trial -
JNJ-80202135, Placebo subcutaneous without Nipocalimab
Janssen-Cilag International N.V.
Sjögren's Disease
1 trial -
JNJ-90301900 (NBTXR3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Carcinoma, Squamous Cell
1 trial -
JNT-517 Placebo, JNT-517, JNT-517
Otsuka Beijing Research Institute
Phenylketonuria
1 trial -
JR-141
Lacuna Pharma Pty Ltd
Mucopolysaccharidosis type II, Hunter Syndrome
1 trial -
JR-141, Elaprase 2 mg/ml concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Mucopolysaccharidosis type II, Hunter Syndrome
1 trial -
JS001
Shanghai University of Traditional Chinese Medicine
Triple-Negative Breast Cancer
1 trial -
JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.
Lacuna Pharma Pty Ltd
Acute ischemic stroke
1 trial -
JZP-110
Jazz Pharmaceuticals Ireland Limited
Narcolepsy
3 trials -
JZP-110
Jazz Pharmaceuticals Ireland Limited
Obstructive Sleep Apnea
3 trials -
Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517
Boehringer Ingelheim
Type 2 diabetes, hypertension, cardiovascular disease
1 trial -
Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets
Boehringer Ingelheim
Chronic kidney disease in paediatric patients
1 trial -
Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673
BEONE MEDICINES AUS PTY LTD
Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)
1 trial -
Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets
Otsuka Beijing Research Institute
Autosomal Recessive Polycystic Kidney Disease
1 trial -
Jivi 500 IU powder and solvent for solution for injection, Jivi 1000 IU powder and solvent for solution for injection
Bayer AG
Severe hemophilia A (<1% FVIII:C)
1 trial -
Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets
Alfasigma S.p.A.
Rheumatoid arthritis
1 trial -
Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP
Alfasigma S.p.A.
Ulcerative Colitis (UC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources